A SCID-hu in vivo model of human Waldenström macroglobulinemia

Blood

Volumn 106, Issue 4, 2005, Pages 1341-1345

  Tassone, Pierfrancesco ^b   Neri, Paola ^b   Kutok, Jeffery L ^b   Tournilhac, Olivier ^b   Santos, Daniel Ditzel ^b   Hatjiharissi, Evdoxia ^b   Munshi, Vidit ^b   Venuta, Salvatore ^b   Anderson, Kenneth C ^b   Treon, Steven P ^b   Munshi, Nikhil C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M; PARAPROTEIN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; BONE TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIGHT CHAIN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR REGRESSION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 23744439045     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-11-4477     Document Type: Article

References (26)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110-115.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
3. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
4. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003;4:679-685.
5. Al-Katib A, Mohammad R, Hamdan M, Mohamed AN, Dan M, Smith MR. Propagation of Waldenstrom's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. Blood. 1993;81:3034-3042.
6. Al-Katib AM, Mensah-Osman E, Aboukameel A, Mohammad R. The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:313-317.
7. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science. 1988;241:1632-1639.
8. Namikawa R, Ueda R, Kyoizumi S. Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood. 1993;82:2526-2536.
9. Kyoizumi S, Baum CM, Kaneshima H, McCune JM, Yee EJ, Namikawa R. Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood. 1992;79:1704-1711.
10. Kyoizumi S, Murray LJ, Namikawa R. Preclinical analysis of cytokine therapy in the SCID-hu mouse. Blood. 1993;81:1479-1488.
11. Akkina RK, Rosenblatt JD, Campbell AG, Chen IS, Zack JA. Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood. 1994;84:1393-1398.
12. Chen BP, Galy A, Kyoizumi S, et al. Engraftment of human hematopoietic precursor cells with secondary transfer potential in SCID-hu mice. Blood. 1994;84:2497-2505.
13. Sandhu JS, Clark BR, Boynton EL, et al. Human hematopoiesis in SCID mice implanted with human adult cancellous bone. Blood. 1996;88:1973-1982.
14. Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997;90:754-765.
15. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92:2908-2913.
16. Anderson KC. Targeted therapy for multiple myeloma. Semin Hematol. 2001;38:286-294.
17. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2:927-937.
18. Anderson KC. Moving disease biology from the lab to the clinic. Cancer. 2003;97:796-801.
19. + multiple myeloma cells. Cancer Res. 2004;64:4629-4636.
20. Tassone P, Goldmacher VS, Neri P, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD 138- multiple myeloma cells. Blood. 2004;104:3688-3696.
21. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol. 1999;10:1525-1527.
22. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
23. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol. 2000;27:79-95.
24. Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother. 2001;24:272-279.
25. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol. 2002;20:2327-2333.
26. Sohop RF, Fonseca R. Genetics and cytogenetics of Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:142-145.